| CGN Resources Limited (CGR) ORDINARY FULLY PAID |
Materials |
$9 |
Drilling Commences at Webb Project
|
28 Apr 2025 9:14AM |
$0.090 |
$0.085 |
fallen by
5.56%
|
|
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$2,727 |
Update - Notification of buy-back - ORA
|
28 Apr 2025 9:14AM |
$1.795 |
$2.210 |
risen by
23.12%
|
|
| Region Group (RGN) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$2,714 |
Update - Notification of buy-back - RGN
|
28 Apr 2025 9:13AM |
$2.280 |
$2.350 |
risen by
3.07%
|
|
| Mirrabooka Investments Limited (MIR) ORDINARY FULLY PAID |
Financials |
$692 |
Letter to Shareholders - Shareholder Information Meetings
|
28 Apr 2025 9:13AM |
$3.220 |
$3.100 |
fallen by
3.73%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$820 |
Letter to Shareholders - Shareholder Information Meetings
|
28 Apr 2025 9:13AM |
$3.020 |
$3.120 |
risen by
3.31%
|
|
| Bathurst Resources Limited (BRL) ORDINARY FULLY PAID |
Materials |
$164 |
Application for quotation of securities - BRL
|
28 Apr 2025 9:13AM |
$0.740 |
$0.685 |
fallen by
7.43%
|
|
| Iron Road Limited (IRD) ORDINARY FULLY PAID |
Materials |
$20 |
Update - Notification of buy-back - IRD
|
28 Apr 2025 9:12AM |
$0.042 |
$0.024 |
fallen by
42.86%
|
|
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$123 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2025 9:12AM |
$0.120 |
$0.138 |
risen by
14.58%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Gross revenue for Q3 FY24 increased by 45% to $22.4 million compared to the prior quarter.
- Bubs' revenue from China grew by 77% quarter-on-quarter due to cross-border e-commerce channel realignment.
- The US business saw a 27% quarter-on-quarter increase in gross revenue, driven by FDA approval for 15 Bubs and Aussie Bubs infant formula products and expanded retail distribution.
- Australian domestic revenue declined, mainly due to the exit from Daigou and Chemist Warehouse channels.
- The company completed a strategic review, focusing on core international markets and cost efficiencies.
- Net cash inflow from operating activities was $5.7 million for the quarter, with an ending cash balance of $27.4 million.
- Inventory reduced by $4.8 million as part of working capital management initiatives.
- Bubs invested in marketing to support China and US growth, with $3.1 million spent during the quarter.
- No government grants or other external financing received during the quarter.
- The Board and management remain focused on sustainable growth, profitability, and cost discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Waratah Minerals Limited (WTM) ORDINARY FULLY PAID |
Materials |
$161 |
Drilling Extends Spur Gold Corridor
|
28 Apr 2025 9:11AM |
$0.190 |
$0.520 |
risen by
173.68%
|
|
WTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful extension of the Spur Gold Corridor at the Spur Project through recent drilling.
- Drilling confirmed significant gold mineralization with multiple high-grade intercepts.
- The gold system has been expanded both laterally and at depth.
- Mineralization remains open in several directions, indicating further exploration potential.
- Follow-up drilling is planned to extend and infill resource areas.
- Results reinforce the Spur Gold Corridor as a core asset for Waratah Minerals Limited.
- Company intends to continue aggressive exploration and resource delineation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$46 |
Appendix 4C & Quarterly Update
|
28 Apr 2025 9:11AM |
$0.120 |
$0.085 |
fallen by
29.17%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurizon Therapeutics Limited (NUZ) published its Appendix 4C and Quarterly Update for the quarter ending March 31, 2024.
- The company advanced its NRX-101 Phase 2b/3 clinical trial, recruiting patients and progressing towards key clinical milestones.
- Ongoing development of additional pipeline assets, NRX-102 and NRX-103, continues.
- Active engagement with the US FDA regarding clinical programs and regulatory pathways.
- NUZ is pursuing business development opportunities, including potential partnerships and collaborations.
- The company reported a cash position sufficient to support ongoing clinical development and operations.
- Expenditure for the quarter was provided, with details on research, administrative, and operational costs.
- NUZ remains focused on its mission to develop therapies for unmet needs in neuropsychiatric and neurological disorders.
- The report outlines anticipated upcoming milestones and future financial runway.
- No dividends or payments to related parties were made during the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurotech International Limited (NTI) ORDINARY FULLY PAID |
Health Care |
$18 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2025 9:10AM |
$0.027 |
$0.014 |
fallen by
48.15%
|
|
NTI - Price-sensitive ASX Announcement
Full Release
Key Points
- NTI reported ongoing progress in clinical trials for NTI164 targeting ASD, with positive Phase II/III results and regulatory engagement.
- Advancement in additional clinical studies for indications such as Rett Syndrome and PANDAS/PANS.
- Commercialisation efforts continued in Australia and international markets, with further product promotions and distribution partnerships.
- Financial update included total cash receipts, grant and rebate income, and detailed summary of quarterly expenditures.
- Ending cash balance was reported as adequate, with no payments to related parties beyond standard remuneration.
- NTI remains focused on advancing clinical programs, regulatory submissions, and commercialisation strategies for NTI164.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$319 |
Letter to Shareholders - Shareholder Information Meetings
|
28 Apr 2025 9:10AM |
$1.050 |
$1.010 |
fallen by
3.81%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$66 |
Update - Notification of buy-back - PCG
|
28 Apr 2025 9:09AM |
$0.740 |
$0.670 |
fallen by
9.46%
|
|
| Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID |
Health Care |
$78 |
CLEO to Fast Track Development of Ovarian Cancer Test
|
28 Apr 2025 9:09AM |
$0.440 |
$0.605 |
risen by
37.50%
|
|
COV - Price-sensitive ASX Announcement
Full Release
Key Points
- Cleo Diagnostics Ltd (CLEO) is advancing the COV ovarian cancer diagnostic test.
- The company is implementing a fast-track strategy to accelerate COV’s development and regulatory approval.
- COV uses a proprietary biomarker panel for sensitive and specific detection of ovarian cancer.
- Recent clinical validation steps and regulatory planning have been successfully completed.
- CLEO is pursuing strategic partnerships to facilitate rapid commercialisation.
- There is a significant market need for improved ovarian cancer diagnostics.
- The COV test targets a large and underserved global market.
- Management anticipates value creation for shareholders via accelerated development and commercialisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$188 |
Recce Enters into USA Department of Defense R&D Agreement
|
28 Apr 2025 9:09AM |
$0.290 |
$0.650 |
risen by
124.14%
|
|
RCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Recce Pharmaceuticals entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA).
- The agreement aims to evaluate Recce’s lead anti-infective compound, RECCE® 327 (R327), for its in vitro and in vivo activity against select biothreat pathogens.
- Collaboration is designed to advance R327’s development for defense and security applications.
- Recce will retain all rights to its technology and any resultant intellectual property from the partnership.
- This partnership reflects Recce’s ongoing strategy of collaborating with international government agencies.
- The agreement is expected to enhance the global profile of Recce and its products, particularly in the area of defense and emerging infectious diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian United Investment Company Limited (AUI) ORDINARY FULLY PAID |
Financials |
$1,398 |
Update - Notification of buy-back - AUI
|
28 Apr 2025 9:09AM |
$10.360 |
$11.300 |
risen by
9.07%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$721 |
Weekly Estimate NTA for 25.04.2025
|
28 Apr 2025 9:08AM |
$2.860 |
$3.420 |
risen by
19.58%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,357 |
Update - Notification of buy-back - NEU
|
28 Apr 2025 9:08AM |
$11.340 |
$18.610 |
risen by
64.11%
|
|
| Gorilla Gold Mines Ltd (GG8) ORDINARY FULLY PAID |
Materials |
$376 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2025 9:08AM |
$0.475 |
$0.515 |
risen by
8.42%
|
|
GG8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities and Appendix 5B Cash Flow Report released for the period ending 31 March 2024
- Continued gold exploration and early-stage development at the Wa Project in the Ashanti gold belt, Ghana
- Commencement of maiden diamond drilling program following successful mapping, soil sampling, and geophysical surveys
- Grant of two new prospecting licenses, increasing total landholding
- Expenditures focused on exploration, drilling, and project development activities
- Maintenance of a prudent cash position throughout the reporting quarter
- Ongoing engagement with local communities and stakeholders
- No gold production or receipts from customers during the quarter
- Appendix 5B outlines detailed cash flow, with primary outflows related to exploration and staff costs
- Company remains committed to aggressive exploration and value creation for shareholders
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sierra Nevada Gold Inc. (SNX) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$16 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2025 9:08AM |
$0.017 |
$0.032 |
risen by
88.24%
|
|
SNX - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities/Appendix 5B Cash Flow Report released for the quarter ending 31 March 2023.
- Active exploration across multiple Nevada-based gold and copper projects, including New Pass, Blackhawk, and Colorback.
- Ongoing drilling and geophysical survey programs yielding encouraging results and indicating mineralization potential.
- Assay results from drilling support continued exploration and target generation.
- Permit applications and preparations for subsequent drilling campaigns underway.
- Exploration and evaluation expenditures formed the majority of operational cash outflows.
- Company reported a strong cash position at quarter end to fund future work programs.
- No mining production or development activities reported during the quarter.
- Detailed cash flow breakdown provided in the Appendix 5B as per ASX reporting requirements.
- Strategic focus remains on expanding exploration and identifying significant gold and copper resources in Nevada.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$10 |
Notice of 2025 AGM and Proxy Form
|
28 Apr 2025 9:07AM |
$0.059 |
$0.054 |
fallen by
8.47%
|
|
| KKR Credit Income Fund (KKC) ORDINARY UNITS FULLY PAID |
Financials |
$739 |
Net Tangible Asset Backing
|
28 Apr 2025 9:07AM |
$2.230 |
$2.290 |
risen by
2.69%
|
|
| Latitude Group Holdings Limited (LFS) ORDINARY FULLY PAID |
Financials |
$1,081 |
CEO Share Trading
|
28 Apr 2025 9:07AM |
$1.140 |
$1.040 |
fallen by
8.77%
|
|
| Killi Resources Limited (KLI) ORDINARY FULLY PAID |
Materials |
$6 |
Board and Management Update
|
28 Apr 2025 9:07AM |
$0.040 |
$0.045 |
risen by
12.50%
|
|
KLI - Price-sensitive ASX Announcement
Full Release
Key Points
- Killi Resources Limited appointed Mr. Jonathan Battershill as its new Managing Director.
- Former Managing Director Ms. Kathryn Cutler will take on the role of Technical Director.
- The company highlighted the strong technical and corporate backgrounds of its Board members.
- Killi is focused on advancing gold and copper exploration projects in Western Australia and Queensland.
- The Board restructure aims to position the company for its next phase of exploration and corporate growth.
- Shareholder value remains a key focus for the company through ongoing resource development initiatives.
- The announcement reflects Killi’s proactive approach in strengthening its leadership and operational capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$4,181 |
Update - Notification of buy-back - ZIP
|
28 Apr 2025 9:06AM |
$1.675 |
$3.290 |
risen by
96.42%
|
|
Call 1300 880 160
Start a chat
Schedule a call
